Karen Reckamp, MD, MS Medical Director, Clinical Research Operations explains Refine Patient Subsets & Define Combinations at the 2018 Oncology…
Browsing: Acute Lymphoblastic Leukemia
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations explains New Lung Cancer Data Already in the Forefront Upcoming meetings…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares First-Line Therapy for Squamous Cell Lung Cancer Multiple Positive Trials…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares the Continuation to Refine Understanding of Biomarkers and Find the…
Omid Hamid MD Chief, Translational Research/Immuno-Oncology Director presents, Immunotherapy in Melanoma at the 2018 Oncology Summit in Huntington Beach, CA…
In this weeks video, Dr. Brian G.M. Durie advises that patients discuss with their doctors the many aspects of various…
In this weeks video, Dr. Brian G.M. Durie emphasizes the importance of correctly diagnosing and staging myeloma before beginning treatment…
Robert Uzzo, MD Fox Chase Cancer Center, discusses Several Elements Factor into Rising Drug Costs Time, development, and innovation adds…
In this weeks video, Dr. Brian G.M. Durie explains that the underlying biology of light chain myeloma is very similar…
In this weeks video, Dr. Brian G.M. Durie compares two trials that treat high-risk smoldering multiple myeloma the CESAR trial…
In this weeks video, Dr. Brian G.M. Durie explains the somewhat confusing results of the IFM 2009 trial. BOTTOM LINE:…
In this weeks video, Dr. Brian G.M. Durie defines minimal residual disease (MRD) and explains how MRD-testing can be used…
In this weeks video, Dr. Brian G.M. Durie explains why myeloma patients should discuss the use of supplements with their…
In this weeks video, Dr. Brian G.M. Durie addresses why the cost of patented drugs, such as Revlimid, have not…
Santosh Kesari, MD, PhD, Chair, Department of Neurosciences and Neurotherapeutics, John Wayne Cancer Institute & Pacific Neuroscience Institute examines Immunotherapy…
Sara A Hurvitz, MD, FACP Associate Professor of Medicine Director, Breast Oncology, examines The Role of Immunotherapy in Breast Cancer…
Marwan Fakih, MD, explains Investigating the Tumor Immune Response to Optimize Treatment in Colorectal Cancer at the 2018 Oncology Summit…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations provides an in-depth look at Harnessing the Power of ImmunotherapyLung Cancer…
Karen Reckamp, MD, MS Medical Director, Clinical Research Operations shares Lung Cancer Immunotherapy Advances PDL-1 and Tumor Mutational Burden at…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical…
Immune checkpoint inhibitors are a promising area of therapy, with our understanding of their mechanism of action and the ways…
As our knowledge of immunotherapy increases, so has our understanding of its side effects. In this interview, Naval Daver, MD,…
The use of immune checkpoint inhibitor therapy for acute myeloid leukemia (AML) has progressed drastically over the past several years.…
Aberrations in sonic hedgehog (shh) signaling are known to be associated with certain types of cancer, including acute myeloid leukemia…
Low-dose cytarabine (ara-C) is not generally perceived as a good therapy for AML, particularly in the US, whereas hypomethylating agents…
Therapeutically targeting the sonic hedgehog (shh) signaling pathway for the treatment of acute myeloid leukemia (AML) is an exciting area,…
MOASC Oncology Summit Kick Off March 3rd, 2018. Dr. Warren H. Fong, MD MOASC President kicks off the 2018 Oncology…
A plethora of novel treatments for acute myeloid leukemia (AML) are emerging, providing an increasing choice of therapies and bringing…
A stimulating session on the implications of genomic data for the management of acute myeloid leukemia (AML) and acute lymphoblastic…
An interesting session on the impact of genomic data on the management of acute myeloid leukemia (AML) and acute lymphoblastic…
Interesting results were produced in the PROUD-PV Study (NCT01949805), which compared the treatment of ropeginterferon alpha-2b with hydroxyurea in patients…
An exciting update on the 4-year follow-up of the RESPONSE Trial (NCT01243944) was given by Jean-Jacques Kiladjian, MD, PhD, of…
Treating patients who suffer from myelofibrosis with interferon used to be considered inappropriate due to the drug being poorly tolerated.…
Recent insights from the genomic analysis of acute lymphoblastic leukemia (ALL) were presented at the 1st International Workshop on Acute…
The genomic analysis of acute lymphoblastic leukemia (ALL) is providing novel insights into the disease, which will inform and direct…
With the excitement surrounding novel therapeutics, reliable conventional treatments can often be overlooked. The optimization of standard treatments is a…
Acute myeloid leukemia (AML) is typically a disease affecting older people, and there are increasing numbers of elderly AML patients…
The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, was a great success, with the…
CAR T-cells are a very promising therapeutic for hematological malignancies, with more in development for B-cell compared with T-cell malignancies.…
Immunotherapy is an exciting area, with advocates, sceptics and those who remain undecided without further research. The 1st International Workshop…
Our understanding of acute myeloid leukemia (AML) has made great strides in recent years, informing the direction of therapeutic strategies.…
The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, hosted though-provoking discussion on the topic…
The 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL, hosted an exciting session on treatment…
The use of minimal residual disease (MRD) in the management of acute leukemias is a hotly debated topic. Despite the…